A phase I study of RYI-018 in healthy and non-alcoholic fibrotic liver disease (NAFLD) patients

Trial Profile

A phase I study of RYI-018 in healthy and non-alcoholic fibrotic liver disease (NAFLD) patients

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Namacizumab (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2017 According to a Bird Rock Bio media release, company received approval to initiate this study.
    • 27 Oct 2016 According to Bird Rock Bio media release, company has submitted Clinical Trial Authorization to initiate this study.
    • 27 Oct 2016 According to Bird Rock Bio media release, data from the SAD and MAD are anticipated to be available in Q1 2017 and Q4 2017 respectively.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top